Innovative Approach for a Typology of Treatment Sequences in Early Stage HER2 Positive Breast Cancer Patients Treated With Trastuzumab in the French National Hospital Database

Innovative Approach for a Typology of Treatment Sequences in Early Stage HER2 Positive Breast Cancer Patients Treated With Trastuzumab in the French National Hospital Database

Background: Our objective was to describe the hospital-based systemic treatment sequences in early stage HER2+ breast cancer patients treated with trastuzumab in France in 2016. Methods: This retrospective observational study was based on the national hospital discharge database (PMSI). Patients hos...

Full description

Bibliographic Details
Main Authors:	Olivier Tredan, Marie Laurent, Melina Gilberg, Rim Ghorbal, Alexandre Vainchtock, Joannie Lortet-Tieulent, Martin Prodel, Julien Dupin
Format:	Article
Language:	English
Published:	SAGE Publishing 2022-11-01
Series:	Cancer Informatics
Online Access:	https://doi.org/10.1177/11769351221135134

Similar Items

Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
by: Alena Rudkouskaya, et al.
Published: (2020-12-01)

Costs and mortality associated with HIV: a machine learning analysis of the French national health insurance database
by: Martin Prodel, et al.
Published: (2021-11-01)

In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment
by: Sietske B.M. Gaykema, et al.
Published: (2014-07-01)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
by: Jamunarani Veeraraghavan, et al.
Published: (2021-05-01)

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
by: Izzet Dogan, et al.
Published: (2023-05-01)

A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastases
by: Eurydice Angeli, et al.
Published: (2024-04-01)

The role of HER4 in relation to trastuzumab resistance and prognosis in HER2 positive breast cancer
by: Mohd Nafi, SN
Published: (2014)

Exploring the Combined Action of Adding Pertuzumab to Branded Trastuzumab versus Trastuzumab Biosimilars for Treating HER2+ Breast Cancer
by: Emma Franco-Mateos, et al.
Published: (2024-04-01)

Aggressive HER2-Positive Gastric Cancer in a Young Patient, Refractory in Trastuzumab and Progressive with Trastuzumab-Emtansine Treatment
by: Vildana Goga Çmega, et al.
Published: (2024-03-01)

Comparing pyrotinib with trastuzumab and pertuzumab with trastuzumab for HER2-positive metastatic breast cancer: a retrospective, multicenter analysis
by: Shuhui You, et al.
Published: (2023-12-01)

Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort
by: Fabien Moinard-Butot, et al.
Published: (2022-06-01)

Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
by: Juin Park, et al.
Published: (2023-12-01)

Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer
by: Eleni Triantafyllidi, et al.
Published: (2022-08-01)

Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors
by: Alice Indini, et al.
Published: (2021-04-01)

The Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerization and Phosphorylation
by: Babak Nami, et al.
Published: (2019-03-01)

Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer
by: Shannon McLaughlin, et al.
Published: (2023-01-01)

In era of immunotherapy: the value of trastuzumab beyond progression in patients with trastuzumab-resistant HER2-positive advanced or metastatic gastric cancer
by: Hui Wang, et al.
Published: (2024-04-01)

Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
by: Caroline Rönnlund, et al.
Published: (2024-02-01)

Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer
by: Rea Levicki, et al.
Published: (2023-02-01)

Trastuzumab: More than a Guide in HER2-Positive Cancer Nanomedicine
by: Celia Nieto, et al.
Published: (2020-08-01)

Potential Biomarkers Associated with Prognosis and Trastuzumab Response in HER2+ Breast Cancer
by: Ana Carla Castro-Guijarro, et al.
Published: (2023-09-01)

Binding Affinity of Trastuzumab and Pertuzumab Monoclonal Antibodies to Extracellular HER2 Domain
by: Victor L. Cruz, et al.
Published: (2023-07-01)

Modulation of the Tumor Microenvironment with Trastuzumab Enables Radiosensitization in HER2+ Breast Cancer
by: Patrick N. Song, et al.
Published: (2022-02-01)

Trastuzumab emtansine of the treatment of HER2-positive breast cancer with brain metatases
by: L. Yu. Vladimirova, et al.
Published: (2020-12-01)

HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen
by: Scott A Wu, et al.
Published: (2023-09-01)

Anti-HER-2 therapy following severe trastuzumab-induced cardiac toxicity
by: Ibrahim Sadek, et al.
Published: (2017-09-01)

Census and typology of braided rivers in the French Alps
by: Piegay, H, et al.
Published: (2009)

Targeting HER3 or MEK overcomes acquired Trastuzumab resistance in HER2-positive gastric cancer-derived xenograft
by: Mengqi Zhang, et al.
Published: (2022-12-01)

YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development
by: Miwa Fujihara, et al.
Published: (2021-11-01)

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
by: Fei Xing, et al.
Published: (2023-01-01)

Expression of MALAT1 Promotes Trastuzumab Resistance in HER2 Overexpressing Breast Cancers
by: Yanyuan Wu, et al.
Published: (2020-07-01)

Mild Cardiotoxicity and Continued Trastuzumab Treatment in the Context of HER2-Positive Breast Cancer
by: Orianne de la Brassinne Bonardeaux, et al.
Published: (2023-10-01)

Role of Post-Neoadjuvant therapy with trastuzumab emtansine in HER2-positive breast cancer
by: E. V. Lubennikova, et al.
Published: (2021-12-01)

Real world evidence of adjuvant trastuzumab in HER2 positive early breast cancer
by: J. Lluch-Gómez, et al.
Published: (2023-05-01)

Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer
by: Cláudia Vieira, et al.
Published: (2023-01-01)

TRASTUZUMAB BEYOND PROGRESSION IN PATIENTS WITH HER-2/NEU POSITIVE METASTATIC BREAST CANCER
by: Yeşim Eralp
Published: (2009-01-01)

The Effectiveness of Trastuzumab Combined with Sequential Chemotherapy for Metastatic Gastric Carcinoma with Overexpression of HER2
by: Omar Saavedra Santa Gadea, et al.
Published: (2017-07-01)

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
by: Sibylle Loibl, et al.
Published: (2022-09-01)

Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts.
by: McLarty, K, et al.
Published: (2009)

821 The combination of a trastuzumab ISAC and pertuzumab augments anti-tumor efficacy in multiple HER2+ tumor models relative to trastuzumab plus pertuzumab
by: Edith A Perez, et al.
Published: (2023-11-01)